Abstract：OBJECTIVE: To study the immunophenotype and its relationship with clinical characteristics in children with acute lymphoblastic leukemia (ALL). METHODS: Bone marrow or blood samples (2-3 mL) with heparin anticoagulation from 139 children with ALL were obtained, and immunophenotypes were identified by flow cytometry. RESULTS: In 139 ALL children, there were 103 cases (74.1%) of B-ALL, 24 cases (17.3%) of T-ALL, 12 cases of T/B biphenotypic (8.6% of T/BALL). In the 103 children with B-ALL, CD19 (90.3%), CD10 (83.5%) and CD20 (27.2%) were expressed as major antigens. In the 24 children with T-ALL, the major antigens were CD3 (79.2%), CD7 (66.7%) and CD5 (33.3%). In the 12 children with B/T-ALL, T-lymphoid antigens included CD7 (50.0%) and CD5 (41.7%), while the B-lymphoid antigens included CD19 (50.0%) and CD10 (33.3%). Of the 139 children with ALL, 32 cases (23.0%) showed myeloid antigen expression (My+ ALL) and the main expression antigens were CD13, CD33, CD14 and MPO. CD34 was expressed in 31 cases. CD34-positive expression (15.6%) in My+ ALL children was significantly lower than in My-ALL children (24.3%). HLA-DR was expressed in 82 of the 139 ALL children. The expression of CD10, CD34 and HLA-DR in the standard-risk, medium risk, high-risk ALL children was significantly different. There were significant differences in gender and incidence of bleeding between the My+ ALL and My-ALL groups (P<0.05). CONCLUSIONS: Immunetyping can differentiate the sources of leukemic cells. The expression of CD10, CD34 and HLA-DR antigen is related to the clinical classification of ALL.
ZHANG Yao-Dong,TAN Li-Na,HU Qun et al. Immunophenotyping and its clinical significance in childhood acute lymphoblastic leukemia[J]. CJCP, 2012, 14(3): 188-191.
［4］Vormoor HJ. Malignant stem cells in childhood acute lymphoblastic leukemia: the stem cell concept revisited［J］. Cell Cycle, 2009, 8(7):996-999.
［5］Zangrando A, Luchini A, Buldini B, Rondelli R, Pession A, Bicciato S, et al. Immunophenotype signature as a tool to define prognostic subgroups in childhood acute myeloid leukemia［J］.Leukemia, 2006, 20(5):888-891.
［6］Sachdeva MU, Ahluwalia J, Das R, Varma N, Garewal G. Role of FAB classification of acute leukemias in era of immunophenotyping［J］.Indian J Pathol Microbiol, 2006, 49(4):524-527.
［7］Bachir F, Bennani S, Lahjouji A, Cherkaoui S, Harif M, Khattab M, et al.Characterization of acute lymphoblastic leukemia subtypes in moroccan children［J］.Int J Pediatr, 2009, 67(4):801.
［8］Babusikova O, Stevulova L, Fajtova M. Immunophenotyping parameters as prognostic factors in T-acute leukemia patients［J］.Neoplasma, 2009, 56(6):508-513.
［9］Dakka N, Bellaoui H, Bouzid N, Khattab M, Bakri Y, Benjouad A. CD10 and CD34 expression in childhood acute lymphoblastic leukemia in Morocco: clinical relevance and outcome［J］.Pediatr Hematol Oncol, 2009, 26(4):216-231.
［10］Steiner M, Attarbaschi A, Dworzak M, Strobl H, Pickl W, Kornmüller R, et al. Cytochemically myeloperoxidase positive childhood acute leukemia with lymphoblastic morphology treated as lymphoblastic leukemia［J］.J Pediatr Hematol Oncol, 2010, 32(1):e4-e7.
［11］Pui CH, Rubnitz JE, Hancock ML, Downing JR, Raimondi SC, Rivera GK, et al. Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia［J］. J Clin Oncol, 1998, 16(12): 3768-3773.
